Fig. 1.

An 81-year-old man (from the exploratory cohort) treated with pembrolizumab and demonstrating a dissociated response on PET_Interim1 (metabolic response of most lesions, but metabolic progression of a lesion on the right humerus head and of a right supra-clavicular lymph node) and a partial metabolic response on PET_Interim2. On PET_Interim1, immuno-induced thyroiditis (A) and immuno-induced-arthritis (pelvic and shoulder girdles) (B) occurred. On PET_Interim2, an immuno-induced gastritis (C) was also observed. The patient was still benefiting from pembrolizumab 20 months after its initiation